JP2024522065A5 - - Google Patents
Info
- Publication number
- JP2024522065A5 JP2024522065A5 JP2023571283A JP2023571283A JP2024522065A5 JP 2024522065 A5 JP2024522065 A5 JP 2024522065A5 JP 2023571283 A JP2023571283 A JP 2023571283A JP 2023571283 A JP2023571283 A JP 2023571283A JP 2024522065 A5 JP2024522065 A5 JP 2024522065A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- disorder
- polymer
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163189449P | 2021-05-17 | 2021-05-17 | |
| US63/189,449 | 2021-05-17 | ||
| PCT/EP2022/063269 WO2022243285A1 (en) | 2021-05-17 | 2022-05-17 | Formulations of psilocybin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024522065A JP2024522065A (ja) | 2024-06-11 |
| JP2024522065A5 true JP2024522065A5 (enExample) | 2025-03-25 |
Family
ID=82019233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023571283A Pending JP2024522065A (ja) | 2021-05-17 | 2022-05-17 | シロシビンの製剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240261306A1 (enExample) |
| EP (2) | EP4792879A2 (enExample) |
| JP (1) | JP2024522065A (enExample) |
| KR (1) | KR20240009433A (enExample) |
| AU (2) | AU2022277515C1 (enExample) |
| CA (1) | CA3216799A1 (enExample) |
| WO (1) | WO2022243285A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021009037A (es) | 2019-01-30 | 2021-10-13 | Diamond Therapeutics Inc | Composiciones y metodos para el manejo de trastornos. |
| US20240074434A1 (en) * | 2019-04-12 | 2024-03-07 | Jeffrey Hanson Robbins | Composition including effervescent agents, biostimulant, nutrient, and pesticide |
| IL297861A (en) | 2020-05-08 | 2023-01-01 | Psilera Inc | Novel compositions of matter and pharmaceutical compositions |
| CA3238440A1 (en) | 2021-12-30 | 2023-07-06 | Atai Therapeutics, Inc. | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| CA3247344A1 (en) * | 2022-06-09 | 2023-12-14 | Diamond Therapeutics Inc. | AMORPHIC PSILOCYBIN (A-POLYMORPHIC) |
| US20250360148A1 (en) * | 2022-06-22 | 2025-11-27 | Cybin Irl Limited | Solid dispersions of psilocybin |
| WO2024031152A1 (en) * | 2022-08-12 | 2024-02-15 | Woke Pharmaceuticals Pty Ltd | Process for improving powder flow characteristics of a crystalline compound |
| AU2023377801A1 (en) * | 2022-11-07 | 2025-06-19 | Natural MedTech Pty Ltd | Tryptamine formulations and uses thereof |
| JP2026518190A (ja) * | 2023-05-24 | 2026-06-04 | サイレラ インコーポレイテッド | トリプタミン誘導体を含む製剤およびそれらの使用 |
| UY40933A (es) * | 2023-10-11 | 2025-05-15 | Univ Of Padova | Composiciones con derivados de psilocibina y psilocina |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| US20020017295A1 (en) | 2000-07-07 | 2002-02-14 | Weers Jeffry G. | Phospholipid-based powders for inhalation |
| US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| WO2009094431A2 (en) * | 2008-01-23 | 2009-07-30 | Ams Research Corporation | Inflatable medical implant system |
| JP2013103899A (ja) * | 2011-11-11 | 2013-05-30 | Fuji Chem Ind Co Ltd | 難溶性薬物の新規な固体分散体 |
| GB2571696B (en) * | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| WO2020148442A1 (en) * | 2019-01-18 | 2020-07-23 | Merck Patent Gmbh | Method for manufacturing a solid administration form and solid administration form |
| KR20220008824A (ko) * | 2019-04-17 | 2022-01-21 | 컴퍼스 패쓰파인더 리미티드 | 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법 |
| GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| WO2021003467A1 (en) * | 2019-07-04 | 2021-01-07 | Sw Holdings, Inc. | Metered dosing compositions and methods of use of psychedelic compounds |
| US20210015738A1 (en) * | 2019-07-17 | 2021-01-21 | Concept Matrix Solutions | Oral dissolvable film containing psychedelic compound |
| US11000534B1 (en) * | 2020-10-08 | 2021-05-11 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
-
2022
- 2022-05-17 EP EP26189164.2A patent/EP4792879A2/en active Pending
- 2022-05-17 US US18/561,152 patent/US20240261306A1/en active Pending
- 2022-05-17 EP EP22729558.1A patent/EP4340809B1/en active Active
- 2022-05-17 KR KR1020237041239A patent/KR20240009433A/ko active Pending
- 2022-05-17 CA CA3216799A patent/CA3216799A1/en active Pending
- 2022-05-17 JP JP2023571283A patent/JP2024522065A/ja active Pending
- 2022-05-17 AU AU2022277515A patent/AU2022277515C1/en active Active
- 2022-05-17 WO PCT/EP2022/063269 patent/WO2022243285A1/en not_active Ceased
-
2026
- 2026-04-13 AU AU2026202771A patent/AU2026202771A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023540017A5 (enExample) | ||
| JP2022523786A5 (enExample) | ||
| JP6758677B2 (ja) | グルタルイミド誘導体を含む医薬組成物、及び好酸球性疾患を処置するためのその適用 | |
| KR101455548B1 (ko) | 비정형 항정신병약 및 taar1 작용제를 포함하는 조합물 | |
| JP2025505745A5 (enExample) | ||
| JP7051638B2 (ja) | エスシタロプラム医薬組成物 | |
| CN1420776A (zh) | 环氧合酶－2活性的抑制 | |
| TW200522944A (en) | CB1 modulator compounds | |
| JPH08208471A (ja) | 薬物反応の増強作用 | |
| JP2025510942A5 (enExample) | ||
| JP2022514569A5 (enExample) | ||
| JP2025506504A5 (enExample) | ||
| JP2023523770A5 (enExample) | ||
| JP2005508872A5 (enExample) | ||
| US20110104186A1 (en) | Small molecule immunopotentiators and assays for their detection | |
| JP2018203774A (ja) | 精神障害の治療における使用のためのイロペリドン代謝物 | |
| JP2024518685A5 (enExample) | ||
| WO2016101898A1 (zh) | 3-[(苯并[d][1，3]二氧戊环-4-基)-氧基]-3-芳基丙胺类化合物及其应用 | |
| JP2022527865A5 (enExample) | ||
| TW200800148A (en) | Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorders in the depressed patient | |
| RU2009136331A (ru) | Индоловые и бензотиофеновые соединения в качестве модуляторов гистаминового н3-рецептора | |
| JP7791832B2 (ja) | トラジピタントによる下気道感染症の治療 | |
| JP2025512818A5 (enExample) | ||
| JP2022508167A5 (enExample) | ||
| Gamboa et al. | Psychopharmacology in transplant patients |